A 3-Year, Multicenter, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Intra-articular Lorecivivint in Subjects With Osteoarthritis of the Knee in a Real-World Setting (STRIDES-EXTRA)
Latest Information Update: 12 Jan 2022
At a glance
- Drugs Lorecivivint (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Registrational
- Acronyms STRIDES-EXTRA
- Sponsors Biosplice Therapeutics
- 17 Dec 2021 Status changed from recruiting to discontinued.
- 15 Jul 2021 Planned initiation date changed from 1 Jul 2021 to 15 Jul 2021.
- 15 Jul 2021 Status changed from not yet recruiting to recruiting.